VICh-ASSOTsIIROVANNAYa NEFROPATIYa: STRATEGIYa DIAGNOSTIKI I LEChENIYa


如何引用文章

全文:

详细

Pathogenesis, clinical and laboratory signs and symptoms, as well as the natural history and treatment, including highly active antiretroviral therapy, are discussed

作者简介

N Mukhin

V Fomin

参考

  1. Winston J.A. HIV and CKD epidemiology. Adv. Chronic Kidney Dis. 2010; 17(1): 19-25.
  2. Ross M.J., Klotman P.E. Recent progress in HIV-associated nephropathy. J. Am. Soc. Nephrol. 2002; 13: 2997-3004.
  3. Rao T.K., Filippone E.J., Nicastri A.D. et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 1984; 310:669-673.
  4. Pardo V., Aldana M., Colton R.M. et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann. Intern. Med. 1984; 101:429-434.
  5. Ahuja T.S., Borucki M., Funtanilla M. et al. Is the prevalence of HIV-associated nephropathy decreasing? Am. J. Nephrol. 1999; 19(6): 655-659.
  6. Shahinian V., Rajaraman S., Borucki M. et al. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am. J. Kidney Dis. 2000; 35(5): 884-888.
  7. Kopp J.B., Winkler C. HIV-associated nephropathy in African Americans. Kidney Int. 2003; Suppl: S43-S49.
  8. Lucas G.M., Mehta S.H., Atta M.G. et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV seronegative participants followed between 1988 and 2004. AIDS. 2007; 21(18): 2435-2443.
  9. Yalavarthy R., Smith M.L., Edelstein C.L. HIV-associated nephropathy in Caucasians: case report and review of literature. Int. J. STD. AIDS. 2008; 19(11): 789-790.
  10. Cheung C.Y., Wong K.M., Lee M.P. et al. Prevalence of chronic kidney disease in Chinese HIV-infected patients. Nephrol. Dial. Transplant. 2007; 22(11): 3186-3190.
  11. D'Agati V., Suh J.I., Carbone L. et al. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int. 1989; 35: 1358-1370.
  12. Nagata M., Hattori M., Hamano Y. et al. Origin and phenotypic features of hyperplastic epithelial cells in collapsing glomerulopathy. Am. J. Kidney Dis. 1998; 32: 962-969.
  13. Rey L., Viciana A., Ruiz P. Immunopathological characteristics of in situ T-cell subpopulations in human immunodeficiency virus-associated nephropathy. Hum. Pathol. 1995;26:408-415.
  14. Rosenstiel P.E., Gruosso T., Letourneau A.M. et al. HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells. Kidney Int. 2008; 74(8): 1049-1058.
  15. Chander P., Soni A., Suri A. et al. Renal ultrastructural markers in AIDSassociated nephropathy. Am. J. Pathol. 1987; 126: 513-526.
  16. Ross M.J., Bruggeman L.A., Wilson P.D. et al. Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J. Am. Soc. Nephrol. 2001; 12: 2645-2651.
  17. Barisoni L., Kriz W., Mundel P. et al. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10: 51-61.
  18. Lu T.C., He J.C., Klotman P.E. Podocytes in HIV-associated nephropathy. Nephron Clin. Pract. 2007; 106(2): c67-с71.
  19. Husain M., D'Agati V.D., He J.C. et al. HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. AIDS. 2005; 19(17): 1975-1980
  20. He J.C., Husain M., Sunamoto M. et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J. Clin. Invest. 2004; 114(5): 643-651
  21. Husain M., Gusella G.L., Klotman M.E. et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J. Am. Soc. Nephrol. 2002; 13(7): 1806-1815.
  22. Schwartz E.J., Cara A., Snoeck H. et al. Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. J. Am. Soc. Nephrol. 2001; 12(8): 1677-1684.
  23. Sunamoto M., Husain M., He J.C. et al. Critical role for Nef in HIV-1-induced podocyte dedifferentiation. Kidney Int. 2003; 64(5): 1695-1701.
  24. Korgaonkar S.N., Feng X., Ross MD. et al. HIV-1 upregulates VEGF in podocytes. J. Am. Soc. Nephrol. 2008; 19(5): 877-883.
  25. Mikulak J., Singhal P.C. HIV-1 and kidney cells: understanding of viral interaction. Nephron. Exp. Nephrol. 2010; 115:e15-e21.
  26. Mikulak J., Singhal P.C. HIV-1 entry into human podocytes is mediated through lipid rafts. Kidney Int. 2010; 77(1): 72-73.
  27. Gummuluru S., Rogel M., Stamatatos L. et al. Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway. J. Virol. 2003; 77: 12865-12874.
  28. Sakurai N., Kuroiwa T., Ikeuchi H. et al. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol. Dial. Transplant. 2009; 24(8): 2378-2383.
  29. Arora S., Husain M., Kumar D. et al. Human immunodeficiency virus downregulates podocyte apoE expression. Am. J. Physiol. Renal. Physiol. 2009; 297(3): F653-F661.
  30. Chen G., Paka L., Kako Y. et al. Protective role for kidney apolipoprotein E: regulation of mesangial cell proliferation and matrix expansion. J. Biol. Chem. 2001; 276: 49142-49147.
  31. Singhal P.C., Sharma P., Reddy K. et al. HIV-1 gp160 envelope protein modulates proliferation and apoptosis in mesangial cells. Nephron 1997; 76: 284-295.
  32. Kapasi A.A., Fan S., Singhal P.C. Role of 14-3-3epsilon, c-Myc/Max, and Akt phosphorylation in HIV-1 gp 120-induced mesangial cell proliferation. Am. J. Physiol. Renal Physiol. 2001; 280:F333-F342.
  33. Hatsukari I., Singh P., Hitosugi N. et al. DEC-205-Mediated internalization of HIV-1 results in the establishment of silent infection in renal tubular cells. J. Am. Soc. Nephrol. 2007; 18: 780-787.
  34. Khan F., Proulx F., Lingwood C.A. Detergentresistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic pathology. Kidney Int 2009; 75: 1209-1216.
  35. Kapasi A.A., Fan S., Singhal P.C. p300 modulates HIV-1 gp120-induced apoptosis in human proximal tubular cells: associated with alteration of TGF-beta and Smad signaling. Nephron Exp. Nephrol. 2006; 102: e30-e38.
  36. Winston J.A., Bruggeman L.A., Ross M.D. et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N. Engl. J. Med. 2001; 344: 1979-1984.
  37. Freedman B.I., Soucie J.M., Stone S.M. et al. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am. J. Kidney Dis. 1999; 34: 254-258.
  38. Papeta N., Chan K.T., Prakash S. et al. Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. J. Clin. Invest. 2009; 119: 1178-1188.
  39. Nunez M., Saran A.M., Freedman B.I. Gene-gene and gene-environment interactions in HIV-associated nephropathy: A focus on the MYH9 nephropathy susceptibility gene. Adv. Chronic Kidney Dis. 2010; 17(1): 44-51.
  40. Kopp J.B., Smith M.W., Nelson G.W. et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat. Genet. 2008; 40: 1175-1184.
  41. Freedman B.I., Hicks P.J., Bostrom M.A. et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol. Dial. Transplant. 2009; 24(11): 3366-3371.
  42. Freedman B.I., Hicks P.J., Bostrom M.A. et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009; 75(7): 736-745.
  43. Woolley I.J., Kalayjian R., Valdez H. et al. HIV nephropathy and the Duffy antigen/receptor for Chemokines in African Americans. J. Nephrol. 2001; 14(5): 384-387.
  44. Atta M.G., Choi M.J., Longenecker J.C. et al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med 2005:118-1288.
  45. Szczech L.A., Gupta S.K., Habash R. et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004; 66(3): 1145-1152.
  46. Abbott K.C., Hypolite I., Welch P.G. et al. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J. Nephrol. 2001; 14(5): 377-383.
  47. Laradi A., Mallet A., Beaufils H. et al. HIV-associated nephropathy: outcome and prognosis factors. Groupe d' Etudes Néphrologiques d'Ile de France. J. Am. Soc. Nephrol. 1998; 9(12): 2327-2335.
  48. Wali R.K., Drachenberg C.I., Papadimitrou J.C. et al. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998; 352: 783-784.
  49. Szczech L.A., Edwards L.J., Sanders L.L. et al. Protease inhibitors are associated with a slowed progression HIV-related renal diseases. Clin. Nephrol. 2002; 57: 336-341.
  50. Lucas G.M., Eustace J.A., Sozio S. et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18: 541-546.
  51. Schwartz E.J., Szchech L.A., Ross M.J. et al. Highly active antiretroviral therapy and the epidemic of HIV+ end stage renal disease. J. Am. Soc Nephrol. 2005; 16: 2412-2420.
  52. Daugas E., Rougier J.P., Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005; 67: 393-403.
  53. Wyatt C.M., Klotman C.E. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert. Opin. Drug. Saf. 2006; 5: 275-287.
  54. Sudano I., Spieker L.E., Noll G. et al. Cardiovascular disease in HIV infection. Am. Heart J. 2006; 151: 1147-1155.
  55. Kopp J.B., Miller K.D., Mican J.A. et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. 1997; 127: 119-125.
  56. Deray D.G. Ritonavir-induced acute renal failure. Clin. Drug Investig. 1998; 16(2): 175.
  57. Verhelst D., Monge M., Meynard J.L. et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am. J. Kidney Dis. 2002; 40: 1331-1333.
  58. Karras A., Lafaurie M., Furco A. et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin. Infect. Dis. 2003; 36: 1070-1073.
  59. Peyriere H., Reynes J., Rouanet J. et al. Renal dysfunction associated with tenofovir therapy: report of 7 cases. J. Acquir. Immune Defic. Syndr. 2004; 35: 269-273.
  60. Gerard L., Chazallon C., Taburet A.M. et al. Renal function in antiretroviral experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. Antivir. Ther. 2007; 12(1): 31-39.
  61. Yahaya I., Uthman A.O., Uthman M.M.B. Interventions for HIV-associated nephropathy. Cochrane Database Syst. Rew. 2009; 4: CD007183.
  62. Post F.A., Moyle G.J., Stellbrink H.J. et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT Study. J. Acquir. Immune Defic. Syndr. 2010 Apr 24. [Epub ahead of print]
  63. Kimmel P.L., Mishkin G.J., Umana W.O. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am. J. Kidney Dis. 1996; 28(2): 202-208.
  64. Wei A., Burns G.C., Williams B.A. et al. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int. 2003; 64: 1462-1471.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##